These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33016238)

  • 21. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Healy BC; Zurawski J; Gonzalez CT; Chitnis T; Weiner HL; Glanz BI
    Mult Scler; 2019 Nov; 25(13):1791-1799. PubMed ID: 30381985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the construct validity and responsiveness of Preference-Based Measures (PBMs) in cataract surgery patients.
    Breheny K; Hollingworth W; Kandiyali R; Dixon P; Loose A; Craggs P; Grzeda M; Sparrow J
    Qual Life Res; 2020 Jul; 29(7):1935-1946. PubMed ID: 32080789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.
    Xin Y; McIntosh E
    Qual Life Res; 2017 Jan; 26(1):1-23. PubMed ID: 27778141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural and construct validity of the Leeds Multiple Sclerosis Quality of Life scale.
    Ensari I; Motl RW; McAuley E
    Qual Life Res; 2016 Jun; 25(6):1605-11. PubMed ID: 26660145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS
    Dewitt B; Feeny D; Fischhoff B; Cella D; Hays RD; Hess R; Pilkonis PA; Revicki DA; Roberts MS; Tsevat J; Yu L; Hanmer J
    Med Decis Making; 2018 Aug; 38(6):683-698. PubMed ID: 29944456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS®).
    Ware JE; Gandek B; Guyer R; Deng N
    Health Qual Life Outcomes; 2016 Jun; 14():84. PubMed ID: 27255462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple sclerosis in the UK: service use, costs, quality of life and disability.
    McCrone P; Heslin M; Knapp M; Bull P; Thompson A
    Pharmacoeconomics; 2008; 26(10):847-60. PubMed ID: 18793032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health Utilities for Multiple Sclerosis.
    Hawton A; Green C
    Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of Life and Mental Health in Multiple Sclerorsis Patients in Bosnia and Herzegovina Measured by Generc and Disease-Specific Questionaire.
    Čatić T; Čulig J; Suljić E; Mašić A; Gojak R
    Psychiatr Danub; 2020 Nov; 32(Suppl 4):505-510. PubMed ID: 33212456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conceptual Underpinnings of the Quality of Life in Neurological Disorders (Neuro-QoL): Comparisons of Core Sets for Stroke, Multiple Sclerosis, Spinal Cord Injury, and Traumatic Brain Injury.
    Wong AWK; Lau SCL; Fong MWM; Cella D; Lai JS; Heinemann AW
    Arch Phys Med Rehabil; 2018 Sep; 99(9):1763-1775. PubMed ID: 29625094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Curtis BH; Reaney M; Landrian AS
    Health Qual Life Outcomes; 2015 Dec; 13():192. PubMed ID: 26627874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.
    Naci H; Fleurence R; Birt J; Duhig A
    J Med Econ; 2010 Mar; 13(1):78-89. PubMed ID: 20047364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility values in the visually impaired: comparing time-trade off and VisQoL.
    Gothwal VK; Bagga DK
    Optom Vis Sci; 2013 Aug; 90(8):843-54. PubMed ID: 23628757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25.
    Rentz AM; Kowalski JW; Walt JG; Hays RD; Brazier JE; Yu R; Lee P; Bressler N; Revicki DA
    JAMA Ophthalmol; 2014 Mar; 132(3):310-8. PubMed ID: 24435696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab.
    Hersh CM; Pang M; Miller DM; McGinley MP; Hyland M; Ziemssen T; Avila RL
    Neurodegener Dis Manag; 2024; 14(2):21-33. PubMed ID: 38623894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
    McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
    Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neurology quality-of-life measurement initiative.
    Cella D; Nowinski C; Peterman A; Victorson D; Miller D; Lai JS; Moy C
    Arch Phys Med Rehabil; 2011 Oct; 92(10 Suppl):S28-36. PubMed ID: 21958920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.